Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment | Zendy

John J.P. Kastelein | Zendy; Wim A. van der Steeg | Zendy; Ingar Holme | Zendy; Michael Gaffney | Zendy; Nilo B. Cater | Zendy; Philip J. Barter | Zendy; Prakash Deedwania | Zendy; Anders Olsson | Zendy; S. Matthijs Boekholdt | Zendy; David A. DeMicco | Zendy; Michael Szarek | Zendy; John C. LaRosa | Zendy; Terje R. Pedersen | Zendy; Scott M. Grundy | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Lipids, Apolipoproteins, and Their Ratios in Relation to Cardiovascular Events With Statin Treatment

Author(s) -

John J.P. Kastelein,

Wim A. van der Steeg,

Ingar Holme,

Michael Gaffney,

Nilo B. Cater,

Philip J. Barter,

Prakash Deedwania,

Anders Olsson,

S. Matthijs Boekholdt,

David A. DeMicco,

Michael Szarek,

John C. LaRosa,

Terje R. Pedersen,

Scott M. Grundy

Publication year - 2008

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.107.713438

Subject(s) - medicine , statin , cholesterol , ldl cholesterol , cardiovascular event , hydroxymethylglutaryl coa reductase inhibitors , atherosclerotic cardiovascular disease , pharmacology , disease

Low-density lipoprotein (LDL) cholesterol is the principal target of lipid-lowering therapy, but recent evidence has suggested more appropriate targets. We compared the relationships of on-treatment levels of LDL cholesterol, non-high-density lipoprotein (HDL) cholesterol, and apolipoprotein B, as well as ratios of total/HDL cholesterol, LDL/HDL cholesterol, and apolipoprotein B/A-I, with the occurrence of cardiovascular events in patients receiving statin therapy.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research